Portola Pharmaceuticals, Inc.
PTLA
PTLA was delisted on the 1st of July, 2020.
151 hedge funds and large institutions have $1.12B invested in Portola Pharmaceuticals, Inc. in 2016 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 56 increasing their positions, 47 reducing their positions, and 27 closing their positions.
69% more call options, than puts
Call options by funds: $12.2M | Put options by funds: $7.24M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
19% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 47
5% less funds holding
Funds holding: 159 → 151 (-8)
9% less capital invested
Capital invested by funds: $1.24B → $1.12B (-$116M)
26% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$46.1M |
| 2 |
Goldman Sachs
New York
|
+$16.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$9.46M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$4.69M |
| 5 |
SO
STRS Ohio
Columbus,
Ohio
|
+$4.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$58.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$14.3M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$13.6M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$12.9M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$11.4M |
PTLA Hedge Fund Activity: Q3 2016 in Review
151 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q3 2016, worth a combined $1.12B — down 9.4% from $1.24B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of PTLA and 20 opened new positions — a net loss of 7 holders — while 47 trimmed existing stakes and 56 added.
The largest buyer was Deerfield Management, adding an estimated $46.1M. The largest seller was Fidelity Investments, cutting an estimated $58.5M.
- 151 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q3 2016, down from 159 in Q2 2016.
- Funds reported $1.12B of Portola Pharmaceuticals, Inc. stock for Q3 2016, down 9.4% quarter-over-quarter.
- 20 funds opened new Portola Pharmaceuticals, Inc. positions in Q3 2016 and 27 closed out, a net change of -7 holders.
- The largest Portola Pharmaceuticals, Inc. buyer in Q3 2016 was Deerfield Management, an estimated $46.1M added.
- The largest Portola Pharmaceuticals, Inc. seller in Q3 2016 was Fidelity Investments, an estimated $58.5M sold.
Based on aggregated 13F filings for Q3 2016.